

Noncemented total knee arthroplasty with a local prophylactic anti-infection agent: a prospective series of 135 cases

Michel Assor, MD

From the Knee and Lower Limb Institute,
University of Marseille, Marseille, France

Accepted for publication
Sept. 30, 2009

Correspondence to:

Dr. M. Assor
Clinique Vert Coteau
96 avenue des Caillols
13012 Marseille
France
michel.assor@free.fr

Background: I conducted a prospective study to assess the effectiveness of an absorbable calcium hydroxyapatite (Hac) layer mixed with vancomycin applied to the articular surface of prosthetic implants in preventing deep infections after noncemented total knee arthroplasty (TKA). This severe complication of TKA occurs in 2%–7% of cases.

Methods: In all, 135 consecutive noncemented TKAs were performed in 126 patients, who were divided into 2 groups. Group 1 comprised 73 knees that received a noncemented implant without any local anti-infection treatment. Group 2 comprised 62 knees that received a noncemented implant with the local anti-infection agent, which consisted of a pasty mixture of 2 g absorbable Hac and 1–2 g vancomycin. The paste was spread in a thin layer on the articular surface of the implants. Patients in both groups received systemic antibiotic therapy.

Results: In group 1 (no local anti-infection agent), there were 3 deep infections (4.1%) in the early (< 2 mo) or intermediate (2 mo to 2 yr) period after surgery, but no signs of loosening. The infections were treated by arthroscopic debridement and antibiotic therapy. There were no infections or loosening of joints in group 2.

Conclusion: This study shows that a local anti-infection treatment is an effective supplement to systemic antibiotic therapy for the prevention of deep infections in noncemented TKA.

Contexte : J'ai procédé à une étude prospective pour évaluer l'efficacité d'une couche d'hydroxyapatite de calcium (Hac) absorbable mélangée avec de la vancomycine appliquée sur la surface articulaire des implants prothétiques pour prévenir les infections profondes après une arthroplastie totale du genou (ATG) non cimentée. Cette complication sévère de l'ATG se produit dans 2 % à 7 % des cas.

Méthodes : Au total, on a pratiqué 135 ATG non cimentées consécutives sur 126 patients répartis en deux groupes. Le Groupe 1 comportait 73 genoux qui ont reçu un implant non cimenté sans traitement anti-infectieux local. Le Groupe 2 comportait 62 genoux qui ont reçu un implant non cimenté et l'agent anti-infectieux local constitué d'une pâte comportant 2 g de Hac absorbable et de 1 à 2 g de vancomycine. La pâte a été appliquée en couche mince sur la surface articulaire des implants. Les patients des deux groupes ont reçu une antibiothérapie systémique.

Résultats : Dans le groupe 1 (aucun agent anti-infectieux local), il y a eu 3 infections profondes (4,1 %) pendant la période qui a suivi immédiatement (< 2 mois) l'intervention chirurgicale ou pendant la période intermédiaire (2 mois à 2 ans), mais il n'y a eu aucun signe de descellement. On a traité les infections par débridement arthroscopique et antibiothérapie. Il n'y a eu aucune infection ni aucun descellement des articulations chez les patients du groupe 2.

Conclusion : Cette étude montre qu'un traitement anti-infectieux local constitue un supplément efficace ajouté à l'antibiothérapie systémique pour prévenir l'infection profonde dans les cas d'ATG non cimentées.

Deep infection in total knee arthroplasty (TKA) is a serious and expensive side effect with serious functional consequences. Many studies on the prevention of deep infection after cemented TKA, in which the articular implants are fixed with acrylic cement (polymethylmethacrylate),

have been reported.^{1–12} The infection rate ranges from 1% to 23%.^{14–31} These studies analyzed the results of systemic perioperative antibiotic prophylaxis, continued for 1 or 2 days after surgery, as well as cement impregnated with antibiotics. Studies on this double prophylaxis, with optimal conditions in terms of asepsis of the operative field and surgical technique, showed that the incidence rate of deep infection was reduced to 2%–7%.

Perioperative antibiotic administration is effective in reducing deep infection rates, but the prevalence is still 2%–7% in most studies. One recent study showed the superiority of double antibiotherapy prophylaxis over systemic antibiotics alone.¹³ It has been experimentally shown that, with use of cement containing vancomycin, the bone concentration of vancomycin was 100 times the minimum inhibitory concentration (MIC) for infection after surgery and up to 4 times the MIC 6 months after surgery.¹⁵

Infection in cemented TKA can lead to prosthetic loosening and bone destruction. Adapted antibiotic treatment alone is not effective because the cement acts as a barrier to osseous diffusion of the antibiotic, and revision surgery, in 1 or 2 sessions, is hard on the patient. Infection in non-cemented TKA, the type of implant I have used since 1988, is easier to treat and does not always require prosthetic revision.

Because the infection rate after knee arthroplasty is still high, I analyzed the results of a prospective series of 135 noncemented TKA patients to assess the effectiveness of a new local anti-infection system consisting of a mixture of absorbable calcium hydroxyapatite (Hac) and vancomycin in preventing of infection after surgery.

METHODS

From 2002 to 2006, 148 patients received 157 consecutive primary noncemented TKAs (9 bilateral). The noncemented TKAs were all of the same type, with tibial stem and condylar plots, with incorporation of the bone into the prosthesis by bone regrowth on a microporous metallic articular surface coated with calcium hydroxyapatite, and with a mobile polyethylene platform without conservation of the cruciate ligaments (types of implants included LCS by DePuy, Score by Amplitude and TKS by Aston Medical).

I systematically performed all kneecap replacements with polyethylene implants that were either cemented (123 cases) or not cemented (implanted in press-fit for TKS in 24 cases). The surgical technique used was identical to the medial parapatellar approach and midvastus, without tourniquet, with electrocoagulation and recovery of the blood loss (Cell Saver by Haemonetics), using deep sutures with Vicryl (Ethicon) and continuous subcutaneous sutures (Vicryl) with fast resorption, in a standard operating room under ultraviolet light without laminar flow ventilation.

The 135 noncemented TKAs were assigned to 1 of 2 groups: without (group 1) or with (group 2) anti-infection

local treatment. The first 12 TKAs were randomly assigned to a group (7 to group 2), and then the subsequent TKS were alternately assigned to group 1 or 2. A pasty mixture of 2 g of an absorbable Hac (either biologic Hac Pro Osteon or synthetic Hac and collagen Collapat II, which is a sponge-like material and easily manipulated; both by Biomet) with 1–2 g vancomycin (powder), and a few drops of physiologic serum were used. The preparation of the mixture was fast (< 1 min). The paste was spread into a thin layer before setting the implants. At the beginning of the study, the paste was spread on the articular surface of the femoral and tibial prosthetic devices. I now spread the paste on the tibial implant or the tibial bone layer.

I measured parameters such as length of surgery, draining and hospital stay, blood loss, transfusions, long-term results, and pre- and postoperative International Knee Society (IKS) scores.

Before surgery, all patients received intravenous antibiotic therapy (cefazoline 500 mg), which was continued during the first 48 hours after surgery (2 g/d). The anesthesia was either regional (spinal) or general (51 patients in group 1, 42 patients in group 2). A crural block was added for 68 knees in group 1 and 56 knees in group 2. For 4 patients in group 2, I obtained samples on day 3 or 4 (the day the drain was removed) of the drained fluid for measurement of vancomycin concentration in the fluid.

After surgery, functional control was measured after 3 and 6 weeks, 3 and 6 months, and then every second year. Radiography was done during the sixth week after surgery, at 6 months and at the last visit. Early (within 2 mo after surgery), intermediate (2 mo to 2 yr) or late (> 2 yr) infections were classified as superficial or deep intra-articular. Deep infections were confirmed by articular fluid culture. I used the Student *t* test to compare the results between the groups.

RESULTS

Of the 148 patients (157 knees) who underwent TKA, 22 were excluded from the study (Fig. 1). Patients lost to follow-up were also excluded. In total, 126 patients who received 135 noncemented TKAs were enrolled in the study. Patients had no signs (no clinical symptoms, normal erythrocyte sedimentation rate and C-reactive protein level) of infection before or during the surgery.

Group 1 comprised 73 knees (68 patients) that received noncemented TKA without the anti-infection agent. The mean age of patients in group 1 was 72 (51–87) years. Most of the patients in this group were female (56 knees). The preoperative diagnosis was primary degenerative arthritis in 67 knees, posttraumatic arthritis in 4 knees and aseptic necrosis in 2 knees.

Group 2 comprised 62 knees (58 patients) that received noncemented TKA; these patients received the anti-infection agent. The mean age in group 2 was 73 (55–89) years, and

most were female (46 knees). The preoperative diagnosis was primary degenerative arthritis in 57 knees, posttraumatic arthritis in 3 knees and aseptic necrosis in 2 knees.

There was no significant difference between the 2 groups ($p > 0.05$) for parameters such as age, sex and preoperative diagnosis (Table 1). There were also no significant differences between group 1 and 2 for the duration of surgery (mean 75 and 80 min, respectively), blood loss (mean 450 and 500 mL), length of draining (3–5 d), duration of hospital stay (6–9 d), knee IKS score before (mean 39 and 41) and after (mean 95 and 96) surgery, and length of follow-up (3–7 yr). The postoperative follow-up was identical for each patient, with walking with a cane and complete support on the second day, active knee mobility and no immobilization device used.

Superficial and localized infections caused by *Staphylococcus epidermidis* were noted in both groups in the early stages of healing (2 infections in group 1 and 1 in group 2). These infections were treated with local and oral antibiotics, without any consequences or significant differences.

At the last follow-up, there were no infections or loosening of implant in either group. The vancomycin concentration in the drained fluid, sampled from 4 cases in group 2, was about 12 times the MIC. In group 1, there were 3 deep infections caused by *Staphylococcus aureus* (4.1%) during the early and intermediate stages; the infections were treated by arthroscopic debridement and antibiotics. The difference between the 2 groups for infection was significant ($p = 0.014$).

DISCUSSION

Perioperative antibiotic treatment is effective in decreas-




Fig. 1. Flow of patients through the study. TKA = total knee arthroplasty.

ing the rate of deep infections, but the infection prevalence remains between 2% and 7% in most series. A recent study showed the superiority of double antibiotic prophylaxis (systemic and in the cement) compared with systemic antibiotic prophylaxis alone.

Infection in noncemented TKA is easier to treat, sometimes without the need for a change of prosthetic device. I began performing noncemented TKA in 1988 because experience with noncemented total hip prosthesis coated with calcium hydroxyapatite (Landos Corail; Landanger /DePuy)^{26,27} demonstrated its longevity.^{27–32} Between 1988 and 2001, I performed 439 noncemented TKAs, with a global infection rate of 3.8% (17 cases, data not shown).

In the present study, the main objective was to assess the effectiveness of a new anti-infection agent in preventing deep infections after noncemented TKA. Three infections (4.1%) developed in the group that did not receive local antibiotic protection; these infections were treated by arthroscopic debridement and antibiotic therapy. No infections developed in the group that received the anti-infection agent. The articular concentration of antibiotics, measured in 4 cases, was above the MIC. The difference in infection rate between the 2 groups was significant.

The lifetime of noncemented TKA is at least equal to that of cemented TKA, as long as there is perfect alignment of the implant and the lower limb and good frontal ligament stability. One advantage of noncemented implants is the easier treatment of aseptic or septic loosening, with less bone destruction due to the presence of cement, which is also a barrier for systemic antibiotic therapy. The use of an antibiotic in an absorbable Hac paste that covers the articular face of the implant allows for

Table 1. Demographic and surgical characteristics of patients included in the study of the effectiveness of a local anti-infection agent during total knee arthroplasty

Characteristic	Group 1 (no anti-infection agent), n = 73	Group 2 (anti-infection agent), n = 62
Age, mean (SD) [range], yr	72 (7.6) [51–87]	73 (8.2) [55–89]
Sex, no. (%) female:male	56 (77) : 17 (23)	46 (74) : 16 (26)
Preoperative diagnosis, no. (%)		
Primary arthritis	67 (92)	57 (92)
Posttraumatic arthritis	4 (5)	3 (5)
Aseptic necrosis	2 (3)	2 (3)
Duration of surgery, mean (range), min	75 (65–90)	80 (70–95)
Blood loss, mean (range), mL	450 (350–650)	500 (350–700)
Duration of draining, d	4 (3–5)	4 (3–5)
Transfusions, no. patients	4	3
Length of hospital stay, mean (range), d	7 (6–9)	7 (6–9)
Follow-up, mean (range), yr	5 (3–7)	5 (3–7)
IKS score, mean (range), points		
Preoperative	39 (28–59)	41 (31–63)
Postoperative	95 (89–97)	96 (90–98)

IKS = International Knee Society; SD = standard deviation.

stronger resistance to infection during the postoperative period because of the bone concentration of antibiotic and the progressive dilution of antibiotic in the articular liquid, coupled with systemic antibiotic therapy. This is a simple procedure that increases the resistance to infection, with no mechanical consequences such as loosening. An additional study involving more patients and a longer follow-up time (10–15 yr) should be performed, and the articular antibiotic concentration should be measured in the first year after surgery.

CONCLUSION

The effectiveness of a new anti-infection system as a complement to systemic antibiotic therapy in the prevention of deep infection after TKA has been demonstrated. Because this method is simple to use and has an extremely low cost, I encourage its use and believe that its use can be extended to include patients at risk of infection (patients with diabetes or previous surgeries).

Competing interests: None declared.

References

1. Wilson MG, Kelley K, Thornhill TS. Infection as a complication of total knee-replacement arthroplasty: risk factors and treatment in sixty-seven cases. *J Bone Joint Surg Am* 1990;72:878-83.
2. Garvin KL, Salvati EA, Brause BD. Role of gentamicin-impregnated cement in total joint arthroplasty. *Orthop Clin North Am* 1988;19:605-10.
3. Grogan TJ, Dorey F, Rollings J, et al. Deep sepsis following total knee arthroplasty: 10 year experience at the University of California at Los Angeles Medical Center. *J Bone Joint Surg Am* 1986;68:226-34.
4. Harris WH, Sledge CB. Total hip and total knee replacement. *N Engl J Med* 1990;323:801-7.
5. Bengtson S, Knutson K, Lidgren L. Treatment of infected knee arthroplasty. *Clin Orthop Relat Res* 1989;245:173-8.
6. Knutson K, Lindstrand A, Lidgren L. Survival of knee arthroplasties: a nation-wide multicentre investigation of 8000 cases. *J Bone Joint Surg Br* 1986;68:795-803.
7. Duff GP, Lachiewicz PF, Kelley SS. Aspiration of the knee joint before revision arthroplasty. *Clin Orthop Relat Res* 1996;331:132-9.
8. Morrey BF, Westholm F, Schoifet S, et al. Long-term results of various treatment options for infected total knee arthroplasty. *Clin Orthop Relat Res* 1989;248:120-8.
9. Jahoda D, Nyc O, Pokorn D, et al. Antibiotic treatment for prevention of infectious complications in joint replacement. *Acta Chir Orthop Traumatol Cech* 2006;73:108-14.
10. Doyon F, Evrard J, Mazas F, et al. Long-term results of prophylactic cefazolin versus placebo in total hip replacement. *Lancet* 1987;1:860.
11. Trippel SB. Antibiotic-impregnated cement in total joint arthroplasty. *J Bone Joint Surg Am* 1986;68:1297-302.
12. Kaiser AB. Antimicrobial prophylaxis in surgery. *N Engl J Med* 1986;315:1129-38.
13. Chiu FY, Lin CF. Antibiotic-impregnated cement in revision total knee arthroplasty: a prospective cohort study of one hundred and eighty-three knees. *J Bone Joint Surg Am* 2009;91:628-33.
14. Langlais F, Lambotte JC, Goldschild M, et al. Symposium de la Société d'orthopédie de l'Ouest (SOO) sur les prothèses totales de genou infectées: traitement adjuvant par ciment antibiothérapie locale. *Ann Orthop Ouest* 1999;31.
15. Norden CW. Prevention of bone and joint infections. *Am J Med* 1985;78:229-32.
16. Josefsson G, Kolmert L. Prophylaxis with systematic antibiotics versus gentamicin bone cement in total hip arthroplasty. A ten-year survey of 1,688 hips. *Clin Orthop Relat Res* 1993;292:210-4.
17. McQueen MM, Hughes SP, May P, et al. Cefuroxime in total joint arthroplasty. Intravenous or in bone cement. *J Arthroplasty* 1990;5:169-72.
18. Rand JA. *Total knee arthroplasty*. New York (NY): Raven Press; 1993.
19. Chiu FY, Lin CF, Chen CM, et al. Cefuroxime-impregnated cement at primary total knee arthroplasty in diabetes mellitus. A prospective, randomised study. *J Bone Joint Surg Br* 2001;83:691-5.
20. Chiu FY, Chen CM, Lin CF, et al. Cefuroxime-impregnated cement in primary total knee arthroplasty: a prospective, randomized study of three hundred and forty knees. *J Bone Joint Surg Am* 2002;84:759-62.
21. Bengtson S, Knutson K, Lidgren L. Treatment of infected knee arthroplasty. *Clin Orthop Relat Res* 1989;245:173-8.
22. Saleh K, Olson M, Resig S, et al. Predictors of wound infection in hip and knee joint replacement: results from a 20 year surveillance program. *J Orthop Res* 2002;20:506-15.
23. Simmons TD, Stern SH. Diagnosis and management of the infected total knee arthroplasty. *Am J Knee Surg* 1996;9:99-106.
24. Teeny SM, Dorr L, Murata G, et al. Treatment of infected total knee arthroplasty. Irrigation and debridement versus two-stage reimplantation. *J Arthroplasty* 1990;5:35-9.
25. Tsukayama DT, Goldberg VM, Kyle R. Diagnosis and management of infection after total knee arthroplasty. *J Bone Joint Surg Am* 2003;85(Suppl 1):S75-80.
26. Argenson JN, Assor M, Aubaniac JM. Hip reconstruction by custom prosthesis: the solution for severe dysplastic and dysmorphic hips. *J Bone Joint Surg Br* 1992;74(Suppl II):184.
27. Vidalain JP; the Artro Group. The corail system in primary THA: results, lessons and comments from the series performed by the ARTRO group (12-year experience). *Eur J Orthop Surg Traumatol* 1999;9:87-90.
28. Assor M, Aubaniac JM. Influence of rotatory malposition of femoral implant in failure of unicompartmental medial knee prosthesis. *Rev Chir Orthop Repar Appar Mot* 2006;92:473-84.
29. Chana R, Shenava Y, Nicholl AP, et al. Five- to 8-year results of the uncemented Duracon total knee arthroplasty system. *J Arthroplasty* 2008;23:677-82.
30. Bassett RW. Results of 1,000 performance knees: cementless versus cemented fixation. *J Arthroplasty* 1998;13:409-13.
31. Silverton CD. Cemented and cementless fixation: results and techniques. *Instr Course Lect* 2006;55:429-37.
32. Gacon G, Coillard JY, Barba L, et al. Uncemented knee prosthesis. Results a propos of 58 cases with a minimum of 5-year follow-up. *Rev Chir Orthop Repar Appar Mot* 1995;81:505-13.